Checkmate 214 Presented by Toni Choueiri, MD.
Dr. Toni Choueiri shares groundbreaking 9-year results from the CHECKMATE-214 trial.
-
1
Dr. Toni Choueiri presented 9-year results from the CHECKMATE-214 trial, a pivotal study in metastatic kidney cancer.
-
2
The trial established nivolumab and ipilimumab as effective immunotherapy, replacing traditional TKI treatments.
-
3
At 9 years, over 30% of patients treated with nivolumab are still alive, a significant improvement from the previous 5% survival rate.
-
4
No new long-term toxicities were observed, and the majority of complete responses remained durable.
-
5
These findings provide long-term safety and efficacy data, offering hope and information for kidney cancer patients.
